For the quarter ending 2025-09-30, INDP had -$332,062 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total research and development | 6,495,677 | - |
| General and administrative | 1,130,764 | - |
| Other income, net | 39,088 | - |
| Change in fair value of convertible promissory notes | -365,718 | - |
| Net loss | -2,975,117 | -9,761,349 |
| Stock-based compensation | 150,614 | 421,654 |
| Change in fair value of convertible promissory notes | 365,718 | 787,703 |
| Prepaid expenses and other current and non- current assets | 357,997 | -821,899 |
| Depreciation | - | 0 |
| Accounts payable and other current liabilities | -249,952 | 1,334,030 |
| Operating lease right-of-use asset and liability, net | -597 | -1,193 |
| Net cash used in operating activities | -2,567,427 | -9,065,316 |
| Proceeds from issuance of convertible promissory notes | 0 | 5,714,800 |
| Proceeds from issuance of shares of common stock and warrants | 2,339,169 | 4,057,719 |
| Proceeds from exercise of pre-funded warrants | 154 | - |
| Issuance costs | 103,958 | 336,255 |
| Net cash provided by financing activities | 2,235,365 | 9,436,264 |
| Net increase (decrease) in cash and cash equivalents | -332,062 | 370,948 |
| Cash and cash equivalents at beginning of period | 5,786,753 | - |
| Cash and cash equivalents at end of period | 5,825,639 | - |
Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. (INDP)